National Laboratory Surveillance of Invasive Streptococcal Disease in Canada - Annual Summary 2017

Executive Summary

Figure A. Invasive S. pneumoniae serotypes in all combined age group

A combination line and stacked bar graph displaying multidrug drug resistance trends from 2013 to 2017 for S pneumoniae.
Figure A - Text Description

Bar graph displaying the percentage of Streptococcus pneumonia serotypes from 2013 to 2017 based on the total number of isolates tested annually.

Column1

2013 (n=2568)

2014 (n=2466)

2015 (n=2593)

2016 (n=2764)

2017 (n=3006)

4Footnote *    (42,57,103,182,229) Footnote

1.6%

2.3%

4.0%

6.6%

7.6%

6BFootnote *   (15,6,10,20,8)

0.6%

0.2%

0.4%

0.7%

0.3%

9VFootnote *   (9,9,7,5,12)

0.4%

0.4%

0.3%

0.2%

0.4%

14Footnote *   (15,10,12,14,23)

0.6%

0.4%

0.5%

0.5%

0.8%

18CFootnote *  (10,5,6,8,6)

0.4%

0.2%

0.2%

0.3%

0.2%

19FFootnote *  (27,23,42,43,73)

1.1%

0.9%

1.6%

1.6%

2.4%

23FFootnote *  (10,10,9,4,2)

0.4%

0.4%

0.3%

0.1%

0.1%

1Footnote **   (10,3,4,3,0)

0.4%

0.1%

0.2%

0.1%

0.0%

3Footnote **   (229,219,235,261,289)

8.9%

8.9%

9.1%

9.4%

9.6%

5Footnote **   (5,0,2,0,0)

0.2%

0.0%

0.1%

0.0%

0.0%

6AFootnote **  (15,16,9,19,6)

0.6%

0.6%

0.3%

0.7%

0.2%

7FFootnote **  (226,184,145,109,111)

8.8%

7.5%

5.6%

3.9%

3.7%

19AFootnote ** (299,220,212,176,143)

11.6%

8.9%

8.2%

6.4%

4.8%

2Footnote ^    (1,0,0,0,0)

0.0%

0.0%

0.0%

0.0%

0.0%

8Footnote ^    (119,99,137,148,151)

4.6%

4.0%

5.3%

5.4%

5.0%

9NFootnote ^   (113,109,115,138,203)

4.4%

4.4%

4.4%

5.0%

6.8%

10AFootnote ^  (47,49,45,48,57)

1.8%

2.0%

1.7%

1.7%

1.9%

11AFootnote ^  (92,99,88,91,90)

3.6%

4.0%

3.4%

3.3%

3.0%

12FFootnote ^  (90,88,126,102,123)

3.5%

3.6%

4.9%

3.7%

4.1%

15B/CFootnote ^(87,85,87,125,114)

3.4%

3.4%

3.4%

4.5%

3.8%

17FFootnote ^  (18,31,17,23,28)

0.7%

1.3%

0.7%

0.8%

0.9%

20Footnote ^   (50,69,88,81,113)

1.9%

2.8%

3.4%

2.9%

3.8%

22FFootnote ^  (312,281,252,254,267)

12.1%

11.4%

9.7%

9.2%

8.9%

33FFootnote ^  (72,56,74,98,100)

2.8%

2.3%

2.9%

3.5%

3.3%

6C    (92,91,74,73,60)

3.6%

3.7%

2.9%

2.6%

2.0%

6D    (3,2,3,0,0)

0.1%

0.1%

0.1%

0.0%

0.0%

7A    (0,0,1,0,0)

0.0%

0.0%

0.0%

0.0%

0.0%

7B    (0,1,2,0,2)

0.0%

0.0%

0.1%

0.0%

0.1%

7C    (12,13,26,42,22)

0.5%

0.5%

1.0%

1.5%

0.7%

9A    (1,0,2,0,0)

0.0%

0.0%

0.1%

0.0%

0.0%

9L    (0,0,0,2,2)

0.0%

0.0%

0.0%

0.1%

0.1%

10B   (1,4,2,2,2)

0.0%

0.2%

0.1%

0.1%

0.1%

10F   (1,1,0,2,3)

0.0%

0.0%

0.0%

0.1%

0.1%

11B   (1,1,4,3,0)

0.0%

0.0%

0.2%

0.1%

0.0%

11D   (0,0,0,0,3)

0.0%

0.0%

0.0%

0.0%

0.1%

11F   (1,0,0,0,0)

0.0%

0.0%

0.0%

0.0%

0.0%

12B   (0,0,0,0,1)

0.0%

0.0%

0.0%

0.0%

0.0%

13    (4,13,7,8,6)

0.2%

0.5%

0.3%

0.3%

0.2%

15A   (99,113,119,123,145)

3.9%

4.6%

4.6%

4.5%

4.8%

16F   (60,72,64,72,72)

2.3%

2.9%

2.5%

2.6%

2.4%

17A   (0,0,1,0,0)

0.0%

0.0%

0.0%

0.0%

0.0%

18A   (2,1,0,1,0)

0.1%

0.0%

0.0%

0.0%

0.0%

18B   (1,0,0,0,0)

0.0%

0.0%

0.0%

0.0%

0.0%

18F   (0,0,0,1,0)

0.0%

0.0%

0.0%

0.0%

0.0%

21    (11,7,9,11,16)

0.4%

0.3%

0.3%

0.4%

0.5%

22A   (1,4,1,0,1)

0.0%

0.2%

0.0%

0.0%

0.0%

23A   (88,107,110,106,140)

3.4%

4.3%

4.2%

3.8%

4.7%

23B   (50,86,78,83,93)

1.9%

3.5%

3.0%

3.0%

3.1%

24    (0,0,2,1,0)

0.0%

0.0%

0.1%

0.0%

0.0%

24A   (0,0,0,1,0)

0.0%

0.0%

0.0%

0.0%

0.0%

24B   (1,0,1,1,1)

0.0%

0.0%

0.0%

0.0%

0.0%

24F   (4,12,18,21,24)

0.2%

0.5%

0.7%

0.8%

0.8%

25F   (0,1,0,0,0)

0.0%

0.0%

0.0%

0.0%

0.0%

28A   (4,2,2,5,10)

0.2%

0.1%

0.1%

0.2%

0.3%

29    (4,13,9,8,4)

0.2%

0.5%

0.3%

0.3%

0.1%

31    (32,39,31,46,43)

1.2%

1.6%

1.2%

1.7%

1.4%

32A   (0,0,0,0,1)

0.0%

0.0%

0.0%

0.0%

0.0%

33A   (10,3,10,4,2)

0.4%

0.1%

0.4%

0.1%

0.1%

33B   (1,0,0,1,0)

0.0%

0.0%

0.0%

0.0%

0.0%

33C   (0,0,0,0,1)

0.0%

0.0%

0.0%

0.0%

0.0%

34    (19,21,25,23,27)

0.7%

0.9%

1.0%

0.8%

0.9%

35A   (3,2,1,4,2)

0.1%

0.1%

0.0%

0.1%

0.1%

35B   (58,45,60,61,73)

2.3%

1.8%

2.3%

2.2%

2.4%

35C   (1,1,1,0,0)

0.0%

0.0%

0.0%

0.0%

0.0%

35F   (44,52,61,54,50)

1.7%

2.1%

2.4%

2.0%

1.7%

37    (4,2,2,2,2)

0.2%

0.1%

0.1%

0.1%

0.1%

38    (36,21,37,46,46)

1.4%

0.9%

1.4%

1.7%

1.5%

42    (0,0,0,0,1)

0.0%

0.0%

0.0%

0.0%

0.0%

NT    (6,8,5,5,3)

0.2%

0.3%

0.2%

0.2%

0.1%

Footnote *

Component of PCV7

Return to footnote * referrer

Footnote **

Component of PCV13

Return to footnote ** referrer

Footnote ^

Component of PPV23

Return to footnote ^ referrer

Footnote ‡

Number of isolates from 2013, 2014, 2015, 2016 and 2017, respectively.

Return to footnote referrer

Figure B. Annual trend of multi-drug resistance of S. pneumoniae

A combination line and stacked bar graph displaying multidrug drug resistance trends from 2013 to 2017 for S pneumoniae.
Figure B - Text Description

A combination line and stacked bar graph displaying multidrug drug resistance trends from 2013 to 2017 for S pneumoniae.

Category 1

Resistant to 7 classesnote de bas de page *

Resistant to 6 classes

Resistant to 5 classes

Resistant to 4 classes

Resistant to 3 classes

Resistant to 2 classes

Resistant to 1 class

Resistant to ≥3 classes

2013 (n=1058)

0.1%

0.0%

2.8%

1.6%

3.0%

4.8%

20.6%

7.6%

2014 (n=1116)

0.0%

0.5%

1.0%

1.5%

2.0%

8.3%

18.3%

5.0%

2015 (n=1128)

0.0%

0.0%

1.8%

2.6%

2.4%

5.2%

18.4%

6.7%

2016 (n=1114)

0.0%

0.1%

0.8%

2.8%

2.5%

6.4%

18.2%

6.2%

2017 (n=1129)

0.0%

0.4%

1.5%

4.6%

3.1%

6.1%

19.5%

9.6%

Footnote *

Antimicrobial classes include: β-lactams (amoxicillin/clavulanic acid, penicillin using meninigitis breakpoints, ceftriaxone using meningitis breakpoints, cefuroxime using parenteral breakpoint, ertapenem, imipenem and meropenem); macrolides (clarithromycin); fluoroquinolones (levofloxacin and moxifloxacin); tetracyclines (doxycycline); folate pathway inhibitors (trimethoprim-sulfamethoxazole); phenicols (chloramphenicol); lincosamides (clindamycin); oxazolidinones (linezolid).

Return to footnote * referrer

Figure C. Invasive S. pyogenes emm types

Bar graph displaying emm types of S. pyogenes from 2013 to 2017 by percentage based on the total number of isolates tested annually.
Figure C - Text Description

Bar graph displaying emm types of S. pyogenes from 2013 to 2017 by percentage based on the total number of isolates tested annually.

Column1

2013 (n=1527)

2014 (n=1704)

2015 (n=1760)

2016 (n=2154)

2017 (n=2473)

1   (352,456,317,323,449)note de bas de page

23.1%

26.8%

18.0%

15.0%

18.2%

2   (35,46,39,31,33)

2.3%

2.7%

2.2%

1.4%

1.3%

3   (36,37,150,132,61)

2.4%

2.2%

8.5%

6.1%

2.5%

4   (86,99,86,98,86)

5.6%

5.8%

4.9%

4.5%

3.5%

5   (6,9,8,11,7)

0.4%

0.5%

0.5%

0.5%

0.3%

6   (55,80,41,57,48)

3.6%

4.7%

2.3%

2.6%

1.9%

9   (14,10,11,11,41)

0.9%

0.6%

0.6%

0.5%

1.7%

11  (65,55,85,64,68)

4.3%

3.2%

4.8%

3.0%

2.7%

12  (73,108,128,137,147)

4.8%

6.3%

7.3%

6.4%

5.9%

18  (0,0,0,5,4)

0.0%

0.0%

0.0%

0.2%

0.2%

22  (22,18,26,25,25)

1.4%

1.1%

1.5%

1.2%

1.0%

28  (94,107,92,97,126)

6.2%

6.3%

5.2%

4.5%

5.1%

29  (1,8,0,2,4)

0.1%

0.5%

0.0%

0.1%

0.2%

41  (18,36,44,37,55)

1.2%

2.1%

2.5%

1.7%

2.2%

44  (4,6,3,4,4)

0.3%

0.4%

0.2%

0.2%

0.2%

48  (0,1,3,5,4)

0.0%

0.1%

0.2%

0.2%

0.2%

49  (4,1,3,12,70)

0.3%

0.1%

0.2%

0.6%

2.8%

53  (49,45,57,26,37)

3.2%

2.6%

3.2%

1.2%

1.5%

58  (4,3,9,22,14)

0.3%

0.2%

0.5%

1.0%

0.6%

59  (37,31,24,49,57)

2.4%

1.8%

1.4%

2.3%

2.3%

63  (0,1,0,1,2)

0.0%

0.1%

0.0%

0.0%

0.1%

68  (55,43,31,40,25)

3.6%

2.5%

1.8%

1.9%

1.0%

73  (3,10,9,8,15)

0.2%

0.6%

0.5%

0.4%

0.6%

74  (2,0,9,172,234)

0.1%

0.0%

0.5%

8.0%

9.5%

75  (14,21,23,33,41)

0.9%

1.2%

1.3%

1.5%

1.7%

76  (6,10,9,8,73)

0.4%

0.6%

0.5%

0.4%

3.0%

77  (36,18,36,36,33)

2.4%

1.1%

2.0%

1.7%

1.3%

80  (33,33,26,22,9)

2.2%

1.9%

1.5%

1.0%

0.4%

81  (17,30,113,160,226)

1.1%

1.8%

6.4%

7.4%

9.1%

82  (43,23,60,104,63)

2.8%

1.3%

3.4%

4.8%

2.5%

83  (34,19,24,32,37)

2.2%

1.1%

1.4%

1.5%

1.5%

87  (36,37,29,37,29)

2.4%

2.2%

1.6%

1.7%

1.2%

89  (136,159,112,107,136)

8.9%

9.3%

6.4%

5.0%

5.5%

90  (2,1,2,0,2)

0.1%

0.1%

0.1%

0.0%

0.1%

91  (19,15,25,38,34)

1.2%

0.9%

1.4%

1.8%

1.4%

92  (8,4,2,3,14)

0.5%

0.2%

0.1%

0.1%

0.6%

93  (0,1,1,3,4)

0.0%

0.1%

0.1%

0.1%

0.2%

94  (3,4,4,7,5)

0.2%

0.2%

0.2%

0.3%

0.2%

101 (28,52,42,110,87)

1.8%

3.1%

2.4%

5.1%

3.5%

102 (3,1,7,5,8)

0.2%

0.1%

0.4%

0.2%

0.3%

104 (0,1,0,1,2)

0.0%

0.1%

0.0%

0.0%

0.1%

106 (0,0,0,0,2)

0.0%

0.0%

0.0%

0.0%

0.1%

112 (0,0,2,0,2)

0.0%

0.0%

0.1%

0.0%

0.1%

114 (13,11,14,17,8)

0.9%

0.6%

0.8%

0.8%

0.3%

115 (13,3,5,6,2)

0.9%

0.2%

0.3%

0.3%

0.1%

118 (35,25,23,29,8)

2.3%

1.5%

1.3%

1.3%

0.3%

128 (0,1,0,2,3)

0.0%

0.1%

0.0%

0.1%

0.1%

162 (0,0,0,0,2)

0.0%

0.0%

0.0%

0.0%

0.1%

169 (2,1,1,2,9)

0.1%

0.1%

0.1%

0.1%

0.4%

232 (0,0,0,0,2)

0.0%

0.0%

0.0%

0.0%

0.1%

Other (31,24,25,23,16)

2.0%

1.4%

1.4%

1.1%

0.6%

Footnote †

Number of isolates from 2013, 2014, 2015, 2016 and 2017, respectively.

Return to footnote referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: